Pharmacoresistance in Epilepsy

ISBN-13: 9783031365256 / Angielski / Twarda / 2023

Opis

This new edition of Pharmacoresistance in Epilepsy addresses all issues relating to drug-resistance in epilepsy, including studies in patients as well in experimental models and presents the basis for an understanding of recent developments in the pathogenesis and treatment of this condition. Important issues associated with drug-resistant epilepsy are reviewed and updated, such as abnormalities in inhibitory mechanisms, neurotoxicity and changes the immune system associated with this disorder, and the development of drug-resistance as consequence of chronic exposure to antiseizure-medications. Considering that a major obstacle is that epilepsy associated with drug-resistance cannot be controlled with the traditional antiseizure medications, specific chapters describe therapeutic strategies to prevent or reduce the progression of the disease with complementary medical therapies, such as transcranial focal stimulation to promote neuroprotection. Pharmacoresistance in Epilepsy is a valuable resource for anyone working in the field, whether studying epilepsy in the lab or treating it in an office.

Spis treści

Chapter 1. Why study Drug Resistant Epilepsy?

Luisa Rocha, Esper Cavalheiro and Alberto Lazarowski.

Chapter 2. Pharmacoresistance in Epilepsy

Daniel San-Juan and Roberto Antonio Cordova Peralta.

Chapter 3. Experimental models for the study of drug-resistant epilepsy.

Monserrat Fuentes-Mejia, Angeles Nuñez-Lumbreras, Christopher Martínez-Aguirre, Luisa Rocha.

Chapter 4. On Complexity and Emergence: Linking the Hypotheses of Pharmacoresistance in Epilepsy  

Gabriel Servilha-Menezes, Alan Talevi and Norberto Garcia-Cairasco.

Chapter 5. Role of High-Frequency Oscillation Networks in Managing Pharmacoresistant Epilepsy

Shennan Aibel Weiss and Richard Staba.

Chapter 6. Transporter hypothesis in pharmacoresistant epilepsies. Is it at the central or peripheral level?

Liliana Czornyj, Jerónimo Auzmendi and Alberto Lazarowski.

Chapter 7. Changes in Targets as an Explanation for Drug Resistance in Epilepsy 

Christopher Martínez-Aguirre, Daniel Fonseca-Barriendos, Saúl Huerta de la Cruz, Monserrat Fuentes-Mejía, and Luisa Rocha.

Chapter 8. Cellular and molecular mechanisms of neuroinflammation in drug-resistant epilepsy.

Octavio Fabián Mercado-Gómez, Virginia Selene Arriaga-Ávila, Angélica Vega-García, Josué Sánchez-Hernández, Adriana Jiménez, Diana Organista-Juárez, Mara A. Guzmán-Ruiz and Rosalinda Guevara-Guzmán.

Chapter 9. Contribution of the antiepileptic drug administration regime to avoid the development and/or establishment of pharmacoresistant epilepsy.

Pietro Fagiolino and Marta Vázquez

Chapter 10. Pharmacogenetics in Epilepsy and Refractory Epilepsy.

Liliana Czornyj, Jerónimo Auzmendi and Alberto Lazarowski

Chapter 11. Seizures Induce Hypoxia or Hypoxia Induces Seizures. A Perverse Relationship that Increases the Risk of SUDEP.

Jerónimo Auzmendi and Alberto Lazarowski.

Chapter 12. Neonatal excitotoxicity triggers degenerative processes related to seizure susceptibility and pharmacoresistance.

Mónica E. Ureña-Guerrero, Antoni Camins-Espuny and Carlos Beas-Zárate.

Chapter 13. Cerebrovascular remodeling and the role of vascular endothelial growth factor in the epileptic brain and pharmacoresistance.

José Luis Castañeda-Cabral, Mónica E. Ureña-Guerrero, and Silvia Josefina López-Pérez.

Chapter 14. The Role of JNK3 in Epilepsy and Neurodegeneration.

Ester Verdaguer, Rubén D. Castro-Torres, Jordi Olloquequi, Jesús Ureña, Miren Ettcheto, Antoni Parcerisas, Antoni Camins and Carme Auladell.

Chapter 15. Application of proteomics in the study of molecular markers in epilepsy.

Maria José da Silva Fernandes, Andressa Sampaio Pereira, Constanza Catalina Paz Rocha Jaures, Mariana Baldini Prudencio and Daniele Suzete Persike.

Chapter 16. GABAergic neurotransmission abnormalities in pharmacoresistant epilepsy: experimental and human studies.

Sandra Orozco-Suárez, Iris Angélica Feria-Romero, Mónica Elisa Ureña-Guerrero, Luisa Rocha, Mario A. Alonso-Vanegas.

    

Chapter 17. Genes involved in pharmacoresistant epilepsy.

Iris E. Martínez-Juárez, Diego A. Barrios-González, Aurelio Jara Prado, Fernando Sotelo-Díaz, Juan A. Calderón Martínez, Georgina J. Mejía del Castillo, Patricia J. Morales Chinga, Adriana Ochoa, Antonio V. Delgado-Escueta.

Chapter 18. Drug-resistant Epilepsy and the Influence of Age, Gender and Comorbid Disorders. 

Jesús Servando Medel-Matus, César E. Santana-Gómez, Ángel Alberto Puig-Lagunes.

Chapter 19. Indications for Intracerebral Recording in Candidates for Epilepsy Surgery

Silvia Oddo, Brenda Giagante and Silvia Kochen.

Chapter 20. On the Development of New Drugs for the Treatment of Drug Resistant Epilepsy: An Update on Different Approaches to Different Hypotheses.

Alan Talevi.

Chapter 21. Physical exercise as a strategy to reduce seizure susceptibility.

Ricardo Mario Arida.

Chapter 22. Ketogenic Diet and Drug-resistant Epilepsy.

Roberto Caraballo.

Chapter 23. Modulating P-glycoprotein Regulation as a Therapeutic Strategy for Pharmacoresistant Epilepsy.

Daniel Perez-Perez, Hiram Luna-Munguia, Heidrun Potschka.

Chapter 24. Vagus Nerve Stimulation for Intractable Seizures.

Mario A. Alonso Vanegas.

Chapter 25. Non Invasive Brain Stimulation as a potential Therapeutic Procedure in drug-resistant epilepsy

Lilia Morales Chacón and Lazaro Gomez Fernandez.

Chapter 26. Effects of transcranial focal electrical stimulation via concentric ring electrodes on seizure activity. 

Walter G. Besio.

O autorze

Luisa Rocha is Professor in the Department of Pharmacobiology of the Center for Research and Advanced Studies in Mexico City, Mexico.

Esper Cavalheiro is Professor Emeritus at the Universidade Federal de Sao Paulo/Escola Paulista de Medicina, Brasil.

Alberto Lazarowski is Full Professor at Universidad de Buenos Aires, Argentina.